Piramal Pharma Ltd Share Price
(PPLPHARMA)
₹219.83▲5.5%
as on 04:01PM, 11 Apr 2025
Piramal Pharma Performance
Day's Low
Day's High
₹212.35Day's Price Range₹222.852 Week's Low
52 Week's High
₹133.752-Week Price Range₹307.9
| Returns % | |
| 1 Month Return | + 6.75 % |
| 3 Month Return | -6.44 % |
| 1 Year Return | + 57.02 % |
| Market Stats | |
| Previous Close | ₹208.37 |
| Open | ₹216.67 |
| Volume | 75.64L |
| Upper Circuit | ₹250.04 |
| Lower Circuit | ₹166.69 |
| Market Cap | ₹29,143.92Cr |
Piramal Pharma Fundamentals
P/E Ratio
732.77
PEG Ratio
1262.52
Market Cap
₹29,143.92 Cr
P/B Ratio
2.54
EPS
0.13
Dividend Yield
0.09
Sector
Pharmaceuticals
ROE
6.53
Mutual Fund Holdings of Piramal Pharma
Piramal Pharma Analyst Rating
based on 10 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 10 analysts offering long term price targets for Piramal Pharma. An average target of ₹296
Source: S&P Global Market Intelligence
Piramal Pharma Share analysis
Piramal Pharma price forecast by 10 analysts
Upside of34.65%
High
₹340
Target
₹296.00
Low
₹255
Piramal Pharma target price ₹296, a slight upside of 34.65% compared to current price of ₹219.83. According to 10 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Piramal Pharma revenue growth forecast
Expected growth rate Q1, FY2027:48.22%
Forecast
Actual
Including amortisation and stock based compensations
Piramal Pharma EPS growth forecast
EPS estimate Q1, FY2027:4515.38%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Piramal Pharma Ltd
Goldman Sachs Initiates Buy Rating for Piramal Pharma - 08 Apr, 2025
Goldman Sachs has initiated coverage on Piramal Pharma with a Buy rating and a target price of ₹275, citing strong profit growth potential and significant margin improvements by FY28.Piramal Pharma Begins Sevoflurane Production, Stock Rises - 02 Apr, 2025
Piramal Pharma has started commercial production of Sevoflurane at its Telangana facility, boosting its manufacturing capabilities. Kotak Securities projects substantial earnings growth, initiating coverage with a buy rating and a ₹300 price target. The stock rose 0.89% to Rs 227.6 following the news.Piramal Pharma Targets $2 Billion by 2030 - 31 Mar, 2025
Piramal Pharma aims to become a $2 billion company by 2030 with a 25% EBITDA margin. The company is investing $80 million to double its sterile injectables capacity in Lexington, Kentucky, by Q1 2027.Kotak Initiates Buy Rating on Piramal Pharma - 27 Mar, 2025
Kotak has initiated coverage on Piramal Pharma with a BUY rating and a target price of Rs 300, indicating a 37% upside. The firm highlights PPL's strong growth potential driven by its diversified CRDMO presence, improved financial discipline, and expected free cash flow generation of Rs 17 billion over four years.Piramal Pharma Shares Rise on Strong Investor Interest - 25 Mar, 2025
Piramal Pharma shares surged 4.85% to Rs 230.20, driven by high trading volumes and strong investor interest. The stock maintains a bullish sentiment, supported by its inclusion in key indices and solid financial ratios.Piramal Pharma Secures Approval for Neoatricon - 20 Mar, 2025
Piramal Critical Care, in partnership with BrePco Biopharma, has received UKMHRA approval for Neoatricon, the first paediatric-strength dopamine infusion for treating hypotension in children. This approval allows Piramal to expand into paediatric critical care in the EU, UK, and Norway.Bajaj Broking Recommends Piramal Pharma Shares - 14 Mar, 2025
Bajaj Broking has set a buying range of ₹193-203 for Piramal Pharma, targeting ₹229, indicating a potential 16% upside. The company is expanding its capacities and witnessing increased demand in its inhalation anaesthesia business in the USA.
Insights on Piramal Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 1 Year
In the last 1 year, PPLPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 1 year, PPLPHARMA stock has moved up by 57.0%
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.21% to 11.66% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 34.95% of holdings in Dec 2024 quarter
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 2.32K Cr → 2.23K Cr (in ₹), with an average decrease of 3.7% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 19.07% to 18.87% in Dec 2024 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 13.73% to 13.68% in Dec 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 22.59 Cr → 3.68 Cr (in ₹), with an average decrease of 83.7% per quarter
Piramal Pharma Financials
Piramal Pharma Index Inclusions
Piramal Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 34.95% | 0.00 | |
| Foreign Institutions | 13.68% | ||
| Mutual Funds | 11.66% | 4.00 | |
| Retail Investors | 18.87% | ||
| Others | 20.85% |
Piramal Pharma Key Indicators
Piramal Pharma Valuation
Piramal Pharma in the last 5 years
Lowest (-516.41x)
January 5, 2024
Industry (50.30x)
April 11, 2025
Today (732.77x)
April 11, 2025
Highest (2011.42x)
June 25, 2024
Piramal Pharma Earnings and Dividends
Piramal Pharma Ltd Earnings Results
Piramal Pharma Ltd’s net profit fell -63.6% since last year same period to ₹3.68Cr in the Q3 2024-2025. On a quarterly growth basis, Piramal Pharma Ltd has generated -83.71% fall in its net profits since last 3-months.
Read More about Earnings ResultsPiramal Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Piramal Pharma Ltd has declared dividend of ₹0.11 - translating a dividend yield of 0.05%.
Read More about Dividends
Piramal Pharma Technicals Summary
Bearish
Neutral
Bullish
Piramal Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Piramal Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹29,143.92 Cr | 3.14% | 0.58 | ₹17 Cr | ₹8,171 Cr | |
| BUY | ₹29,264.79 Cr | 142.95% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹14,628.52 Cr | 41.85% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹4,721.14 Cr | 1.08% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹15,546.04 Cr | 48.01% | 0.68 | ₹218 Cr | ₹1,296 Cr |
About Piramal Pharma
Revenue: ₹2,204.22Cr as on December 2024 (Q4 24)
Net Profit: ₹3.68Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 2022
Chairperson Name: Nandini Piramal
| Organisation | Piramal Pharma |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Piramal Pharma Ltd
What is Piramal Pharma Ltd price today?
Piramal Pharma Ltd share price today stands at ₹219.83, Open: ₹216.67, Previous Close: ₹208.37, High: ₹222.8, Low: ₹212.35, 52 Week High: ₹307.9, 52 Week Low: ₹133.7.
How to Buy Piramal Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Piramal Pharma Ltd shares
What are today's traded volumes of Piramal Pharma Ltd?
Today's traded volume of Piramal Pharma Ltd(PPLPHARMA) is 75.64L.
What is today's market capitalisation of Piramal Pharma Ltd?
Today's market capitalisation of Piramal Pharma Ltd(PPLPHARMA) is ₹29143.92Cr.
What is the 52 Week High and Low Range of Piramal Pharma Ltd?
How much percentage Piramal Pharma Ltd is down from its 52 Week High?
Piramal Pharma Ltd (PPLPHARMA) share price is ₹219.83. It is down -28.60% from its 52 Week High price of ₹307.9
How much percentage Piramal Pharma Ltd is up from its 52 Week low?
Piramal Pharma Ltd (PPLPHARMA) share price is ₹219.83. It is up 64.42% from its 52 Week Low price of ₹133.7